Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Rhythm Pharmaceuticals
ISIN US76243J1051
|WKN A2H5A0
Market cap (in EUR)
6,492 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Healthcare Biopharmaceuticals Other Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 6,492 m |
| EPS, EUR | -2.67 |
| P/B ratio | 74.5 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 168 m |
| Net income, EUR | -174 m |
| Profit margin | -103.57% |
What ETF is Rhythm Pharmaceuticals in?
There are 46 ETFs which contain Rhythm Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of Rhythm Pharmaceuticals is the Harbor Health Care UCITS ETF Accumulating.
Savings plan offers
Here you can find information about the savings plan availability for the stock. You can use the table to compare savings plan offers for the selected savings rate.
Select your savings amount:
| Broker | Rating | Execution fee | Account fee | |
|---|---|---|---|---|
 | 0.00 CHF | 0.00 CHF | View offer* | |
 | 0.00 CHF | 0.00 CHF | View offer* |
Detailed comparison of all offers
Source: justETF Research; as of 10/2026. The offers are sorted in the following way: 1. Rating 2. Execution fee 3. Number of stock savings plans. The number of stock savings plans is rounded. In addition to the fees charged by online brokers, additional costs may apply. The stated fees are thus exclusive of standard market spreads, commissions, product costs and third-party fees. Please note: No guarantee can be given for the completeness, correctness and accuracy of the content listed. The information on the online brokers' homepages is decisive. Investments in securities involve risks.
*Affiliate link
** Important note: We are part of the Scalable Group since 2021 and are a wholly owned subsidiary of Scalable AG. This means that we are economically connected, but operate with editorial independence. Conflicts of interest are avoided because brokers — including Scalable — are evaluated according to uniform, objective criteria. You can view these in our transparent rating system. Ultimately, it’s up to you to decide how and with whom you want to invest.
*Affiliate link
** Important note: We are part of the Scalable Group since 2021 and are a wholly owned subsidiary of Scalable AG. This means that we are economically connected, but operate with editorial independence. Conflicts of interest are avoided because brokers — including Scalable — are evaluated according to uniform, objective criteria. You can view these in our transparent rating system. Ultimately, it’s up to you to decide how and with whom you want to invest.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable).
There is no warranty for completeness, accuracy and correctness for the displayed information. (en-CH)